Bagsværd, Denmark, 25 March 2015 - Novo Nordisk today announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset® 1 and onset® 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid® (insulin aspart) in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively.
For further information
| Media: | ||
| Mike Rulis | +45 3079 3573 | mike@novonordisk.com (mailto:mike@novonordisk.com) |
| Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com (mailto:kiau@novonordisk.com) |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com (mailto:krop@novonordisk.com) |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com (mailto:mrz@novonordisk.com) |
| Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com (mailto:dabo@novonordisk.com) |
| Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com (mailto:fdni@novonordisk.com) |
Company Announcement No 22 2015
Company Announcement No 22 2015 (http://hugin.info/2013/R/1906174/678581.pdf)
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
HUG#1906174
© 2015 GlobeNewswire (Europe)
